Kestra Medical Technologies Reports Strong Growth in Q4 and Fiscal Year 2026
Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a prominent player in the wearable medical device and digital healthcare sector, has announced its financial results for the fourth quarter and fiscal year ending April 30, 2026. The results reflect robust growth driven by an expanding market presence and innovative product offerings.
1. Significant Financial Highlights
Impressive Revenue Growth
Kestra reported a substantial revenue of $28.6 million for the fourth quarter of fiscal year 2026, marking a 66% increase compared to the same quarter last year. The annual revenue for fiscal year 2026 reached $95.1 million, which is a 59% increase from fiscal year 2025. This growth is attributed to an increased market share and the successful expansion of the wearable cardioverter defibrillator (WCD) market.
Expanding Gross Margins
The company's gross margin for Q4 2026 improved to 54.8%, up from 44.3% in the prior year period. For the entire fiscal year, gross margins increased to 51.4%, compared to 40.5% in FY25. This improvement is largely due to volume leverage, a higher proportion of in-network patients, and effective cost management strategies.
2. Operational Achievements
Brian Webster, President and CEO of Kestra, expressed pride in the company’s accomplishments during the fiscal year. He noted that the ASSURE® system has successfully protected 18,000 patients from sudden cardiac arrest, which underscores the company’s commitment to enhancing patient care through innovation.
Commercial Expansion and Strategic Collaborations
During FY26, Kestra made significant strides in its commercial operations, including:
- The prescription of 6,357 ASSURE® systems in Q4, a 63% increase year-over-year.
- A successful launch of a new algorithm update and compelling primary results from an FDA post-approval study.
- An important collaboration with Biobeat Technologies, aimed at enhancing their technological capabilities in the medical device space.
3. Financial Performance Breakdown
Fourth Quarter Results
- Gross Profit: $15.7 million, up from $7.6 million in Q4 FY25.
- Operating Expenses: GAAP operating expenses were $55 million, a slight decrease from $55.8 million in the prior year, while adjusted operating expenses rose to $44.7 million from $29.7 million, reflecting the costs associated with aggressive commercial expansion.
- Net Loss: The GAAP net loss was $38.8 million, an improvement from a loss of $51.1 million during the same quarter last year. The adjusted EBITDA loss was $26.7 million, compared to a loss of $20.3 million in Q4 FY25.
Fiscal Year Results
- Total Revenue: $95.1 million, compared to $59.9 million in FY25.
- Gross Profit: Increased to $48.9 million, up from $24.2 million in the previous year.
- Operating Expenses: Totaled $183.6 million, up from $130.6 million in FY25. Adjusted operating expenses rose to $144.6 million from $100.6 million.
- Net Loss: The GAAP net loss for FY26 was $131.6 million, compared to $113.8 million in FY25, while adjusted EBITDA losses increased to $87 million, compared to $68.4 million in the prior year.
4. Future Outlook
Looking ahead, Kestra Medical Technologies has provided revenue guidance for FY27, projecting revenues of $137 million, which would represent a 44% increase from FY26. The company is optimistic about its growth trajectory, driven by its focus on innovation and commitment to supporting healthcare providers and patients alike.
In summary, Kestra Medical Technologies is poised for continued expansion in the wearable medical device market, with promising financial results and a clear strategic vision for the future.
